NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Velcade, Melphalan and Prednisone
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
What are the signs and symptoms of multiple myeloma? HealthTree University Myeloma
FDA Approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) Monotherapy
NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and Dex High-risk SMM (ITHACA)
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL